Edmond J. LaVoie, Ph.D., Professor and Chair of Medicinal Chemistry in the Ernest Mario School of Pharmacy, and Joachim Messing, Distinguished Professor of Molecular Biology and Director of the Waksman Institute of Microbiology, along with 146 more academic inventors, will be inducted at the Eighth Annual Conference of the National Academy of Inventors at Space Center Houston on April 11, 2019. The 2018 class of Fellows represents 125 research universities and governmental and non-profit research institutes worldwide and are named inventors on nearly 4,000 issued U.S. patents.

The NAI Fellows Program was established to highlight academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. To date, there are over 1,000 NAI Fellows who have generated more than 11,000 licensed technologies and companies, created more than 1.4 million jobs, and generated over $190 billion in revenue.

Edmond J. LaVoie, Ph.D. is Professor and Chair of Medicinal Chemistry in the Ernest Mario School of Pharmacy at Rutgers University. He holds 52 U.S. patents and 91 foreign patents in the field of drug discovery and development, specifically related to novel topoisomerase I and II targeting agents as anticancer agents, novel antiviral drug candidates targeting influenza viral polymerase and new classes of antibiotic agents, 14 of which have been licensed. LaVoie has published 225 peer-reviewed scientific publications, including articles, books and chapters, and has served as Associate Editor of Letter in Drug Design and Discovery, Associate Editor of Current Medicinal Chemistry, Editorial Board Member of Current Medicinal Chemistry-Anticancer Agents and as Expert Reviewer National Science Centre of Poland. He is a five-time recipient of the William Levine Teacher of the Year award.

He is involved in research and development of small molecule therapeutic agents for the treatment of various types of cancers, drug resistant bacterial infections (including MRSA) and regular bacterial infections. He has started two companies, including TAXIS Pharmaceuticals, a biopharmaceutical company dedicated to treating and reducing the threat of current and emergent antimicrobial resistance, and was instrumental in the discovery and development of several important therapeutic candidates, one of which has completed Phase 1 clinical trials, and several others are currently under evaluation.

LaVoie has been a member of American Association of Pharmaceutical Scientists, American Society of Pharmacognosy, Internal Advisory Board for the Cancer Institute of New Jersey, American Association for Cancer Research, American Chemical Society, European Society of Clinical Microbiology and Infectious Disease, Phi Lamda Upsilon, Phi Lamda Sigma, Rho Chi and Sigma X.